SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical-stage oncology company, has announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4). On August 1, 2025, ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who joined the company in July 2025. These inducement grants, approved by the company's Compensation Committee, were issued as a material inducement to employment in line with Nasdaq Rule 5635(c)(4) and are part of the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The stock options have an exercise price equivalent to ORIC's common stock closing price on the grant date, with a vesting schedule where 25% of the shares vest after one year and 1/36th of the remaining shares vest monthly thereafter. Meanwhile, the restricted stock units will vest in one-third increments on each of the first three anniversaries of the grant date. These grants are subject to the terms of the applicable agreements and the 2022 Inducement Equity Incentive Plan.